Vantage 2019 Preview
by Amy Brown,
Jonathan Gardner and
The Biotech Sector:
THE BIG PICTURE
Vibrant and Volatile
While biopharma has been the focus of a lot of attention and activity
recently, Vantage’s assessment of 2019 suggests that it’s headed for rough
waters. Here’s a sample of the metrics and predictions from their insights.
Biopharma is heading into 2019 on very shaky footing. The turmoil has
largely been triggered by fears from beyond the sector. It is hard to predict how much further markets might fall, though most agree that a more
volatile year is approaching.